Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea · Delayed Price · Currency is KRW

17,820

-1,450 (-7.52%)

Oct 12, 2026, 3:30 PM KST

Market Cap	387.64B -45.9%
Revenue (ttm)	40.55M -99.8%
Net Income	18.51B
EPS	-2,752.30
Shares Out	21.75M
PE Ratio	20.94
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	281,775
Open	18,890
Previous Close	19,270
Day's Range	17,770 - 19,000
52-Week Range	17,780 - 146,600
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 5, 2026

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid leukemia and hematologic malignancies; and ORM-1023, which is in pre-clinical trial for the treatment of small cell lung cancer and neuroendocrine tumo... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 475830

Full Company Profile

Financial Performance

In 2025, Orum Therapeutics's revenue was 23.56 million, a decrease of -99.89% compared to the previous year's 20.91 billion. Losses were -41.97 billion, 631.2% more than in 2024.

Financial Statements